Atrial fibrillation is one of the most common arrhythmia. Cardiac mapping technology, an important method to study the electrophysiological mechanism of atrial fibrillation, can determine the abnormal origin and record the distribution and transmission way of these atrial electrical signals. This technology offers a new way for research the electrophysiological mechanism of atrial fibrillation. The purpose of this study is to review the research progress of cardiac mapping in the electrophysiological mechanism of atrial fibrillation and clinical application.
The capacity for self-regeneration of the adult heart is very limited, conventional therapies cannot solve the loss of cardiomyocytes in the infarcted heart leads to continuous ventricular remodeling. Cell transplantation therapy is emerging as a novel approach for myocardial repair over conventional therapies. Various types of cell transplantation have improved cardiac function and angiogenesis in animal models and clinical settings. The safety and feasibility of some clinical trials have been initiated. In this review, we summarize the advantages and limitations of different cell types proposed for cell transplantation in myocardial infarction and give an overview of the clinical trials using this novel therapeutic approach in patients with myocardial infarction.
Atrial fibrillation (AF) is one of the most common arrhythmias. Today, there are a large number of AF patients worldwide, and incidence increases with the increase of age. However, the current diagnosis rate of AF via auxiliary examination is relatively low. In view of the widespread application of artificial intelligence (AI) in the medical field, the diagnosis of AF using AI has also become a research hotspot. This article briefly introduces the relevant aspects of AI and reviews the application of AI in AF prediction.
Atrial fibrillation is a common arrhythmia associated with high mortality and morbidity, and the current treatment of atrial fibrillation is still limited. Histone deacetylase (HDAC) plays an important role in the pathophysiology of cardiovascular disease and promotes the occurrence of atrial fibrillation. Inhibition of HDAC may be a new therapeutic strategy through the regulation of atrial remodeling. Therefore, we reviewed the research progress of the HDAC and atrial fibrillation.
Atrial fibrillation is now the most frequent kind of adult arrhythmia in the world, with a prevalence rate at 2%-4%. In addition to the clinical symptoms of palpitation, shortness of breath, chest tightness, and decreased exercise tolerance, patients with atrial fibrillation have a 4 to 5 times higher risk of ischemic stroke than patients without atrial fibrillation, so anticoagulation therapy should be tailored to the CHA2DS2-VASc [congestive heart failure, hypertension, age≥75 years (doubled), diabetes mellitus, stroke (doubled)-vascular disease, age 65-74 years and sex category (female)] score. Oral anticoagulants not only prevent thrombosis, but also raise the risk of drug-related bleeding. This paper examines the assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A position paper from ESC/EHRA/AACA/APHRS, in order to provide readers with the most up-to-date research on anticoagulant bleeding risk management in patients with atrial fibrillation.